Can You Get Retatrutide Before It's Approved? What Lilly's Expanded-Access Program Actually Means

TL;DR

• A narrow expanded-access pathway opened on 3 August 2026 - it is not FDA approval, not commercial availability, and not a prescription you can fill.
• Every reported criterion must be met at once: refractory obesity at BMI 35 or higher despite the highest available approved therapy, two or more serious obesity-related complications, inability to enrol in a trial, and bariatric surgery already discussed.
• Patients cannot apply directly - a treating physician requests, Lilly must agree to supply, and FDA authorisation plus institutional review board sign-off follow, case by case.
• On 12 August 2026 Lilly filed six lawsuits against US sellers of grey-market retatrutide, spanning compounding pharmacies, online sellers and med spas - civil complaints containing unproven allegations.
• Lilly says it has referred more than 200 entities to the FDA, DOJ, state attorneys general and licensing boards, and identified over 14,000 listings across more than 100 countries.
• Until an approval is granted, no retatrutide-containing product may legally be sold for human use in the US - regardless of how it is labelled or who is selling it.
• The filing is still ahead, not behind: Lilly plans to submit its application in Q1 2027 and, as of 26 October 2026, has not yet submitted it, so this pathway is not a sign that wider access is close.

Educational content, not medical advice. No doses or protocols appear. Retatrutide is investigational and not FDA-approved; expanded access is not approval, a prescription, or commercial availability.

Updated October 2026: re-verified 26 October 2026 against Lilly's 23 July 2026 release. Adds that TRIUMPH-2 and TRIUMPH-3 met their primary endpoints against placebo and that the Q1 2027 BLA is still planned, not filed, so expanded access is not a sign that wider access is near. Corrects "remains in Phase 3". Removes the remaining compound-page link and the supply CTA, which contradicted this page's point that there is no lawful consumer route; replaces them with a bloodwork-first recommendation.

Updated September 2026: pins the filing framing to Lilly's stated Biologics License Application in Q1 2027 (the biologics pathway, not an NDA and not an end-2026 submission) and sets the expanded-access pathway against that window, with an approval realistically no earlier than late 2027 to 2028. Removes the compound-reference links from this page, which is about the absence of a lawful consumer route.

Updated August 2026: added the 12 August 2026 enforcement wave - Eli Lilly has filed six lawsuits against US sellers of gray-market retatrutide, and until any approval no retatrutide-containing product may legally be sold for human use in the US.

---

The headline vs the fine print

In early August 2026, a wave of headlines suggested that ordinary people could finally "get retatrutide before approval." Technically true. Badly misunderstood.

On 3 August 2026, Eli Lilly confirmed it would allow a defined group of patients to apply for early, expanded access to retatrutide - an investigational, not FDA-approved obesity drug. The move formalized a pathway the company had previously granted on a one-off basis to a single, widely discussed compassionate-use case earlier in 2026. That is the entire news event.

What it is not: a launch, an approval, a pharmacy product, or a route most readers could realistically walk. The gap between "a pathway exists" and "you can get it" is enormous here, and that gap is exactly where confusion - and, unfortunately, exploitation - thrives. The rest of this article is about closing that gap honestly.

Nine days later, that gap became the subject of litigation. See The August 2026 enforcement wave below.

What "expanded access" actually is

Expanded access - often called compassionate use - is a regulatory mechanism that lets a patient with a serious or life-threatening condition receive an investigational medicine outside of a clinical trial, when there is no comparable approved option and the patient cannot enroll in a study. When it is structured to serve a group rather than a single person, it is typically organized under a treatment IND (investigational new drug application).

A few distinctions matter, because the headlines blur all of them:

• It is not a clinical trial. In a trial, the primary purpose is to generate data under a controlled protocol. Expanded access exists to treat an individual patient who has run out of options - not to study them.
• It is not a prescription. A physician cannot simply write for retatrutide at a pharmacy. The drug is not approved, so there is nothing to dispense commercially.
• It is not approval. The drug's investigational status is unchanged. Regulators have not concluded it is safe and effective for general use; that determination is what an approval represents, and it has not happened.

Throughout this pathway, retatrutide remains investigational and not FDA-approved. Expanded access changes who might obtain it under narrow, supervised circumstances - it does not change what it is.

Who actually qualifies

Here is where the "you can get it now" framing collapses. The reported eligibility criteria describe a very small, very sick population, and they must all be met at once. Coverage of the announcement (including TechTimes) stressed that the pathway uses "criteria most patients cannot meet."

The table below summarizes the reported eligibility gate as described in press coverage. It is included to explain the news accurately - not as a checklist, not as advice, and not as a suggestion that any reader should pursue this route.

Read those together and the picture is clear: this is a last-resort pathway for patients who have already exhausted approved, monitored care and remain critically ill. It is deliberately narrow. Framing it as a "how to qualify" opportunity misreads both the intent and the reality - the criteria are a gate, not a door.

The process

Even for a patient who meets every criterion, access is not self-directed. The process is layered on purpose.

Patients cannot apply directly to Lilly. The pathway begins with a treating physician who knows the patient's full history and believes the case fits. That physician must support the request and contact the company.

Lilly must agree to supply. The company is not obligated to provide the drug for any given request. If it declines, the pathway ends there.

Regulators and an ethics board must sign off. If Lilly agrees to supply, the request still requires FDA authorization and review by an institutional review board (IRB) before anything proceeds. These are independent checkpoints, not formalities.

In short: physician requests → Lilly agrees to supply → FDA authorization plus IRB review. Each decision is made case by case, and the total number of patients the program will accept is undefined. There is no published quota, no guaranteed timeline, and no assurance of access even for those who clear the clinical bar.

What it is NOT

Because the practical answer for nearly everyone is "no," it is worth being blunt about what this announcement does not mean.

• It is not approval. Retatrutide's regulatory status is unchanged; it remains investigational and not FDA-approved.
• It is not availability. There is no commercial product, no pharmacy stock, and no way to buy it legally as a consumer.
• It is not a route we point anyone toward. Vivre Labs does not treat expanded access as a shortcut, and neither should you.
• It is not a safety or efficacy verdict. A compassionate-use pathway reflects unmet need in desperate cases - not a conclusion that the drug is proven safe and effective for general use.

There is also a real downstream risk. Every time an "access" headline circulates, gray-market and "research-only" sellers weaponize it - implying that because some pathway exists, their unregulated vials are somehow legitimate. They are not. An expanded-access program run through physicians, a manufacturer, the FDA, and an IRB has nothing to do with an anonymous website selling unverified product. If a headline about this program is being used to sell you something, that is the tell.

If you want the wider legal context, see our explainers on whether peptides are legal now in 2026 and whether compounded GLP-1s are legal.

The August 2026 enforcement wave

Dated section - reported as of 20 August 2026.

The "some pathway exists, therefore our vials are fine" argument is now the subject of active litigation.

On 12 August 2026, Eli Lilly filed six lawsuits against US sellers of gray-market retatrutide. The named defendants are:

• Aesthetic Envy Cosmetic Centers (California)
• Astra (Texas)
• Striker (Texas)
• Lone Star Peptide (Texas)
• Legendary Peptides (Texas)
• Texas Peptides (Texas)

What is notable is the mix of business types. These are not all anonymous offshore websites. The defendants span compounding pharmacies, online sellers and med spas - including bricks-and-mortar clinical-looking businesses. A storefront, a clinical aesthetic and a professional-looking website are not, on this evidence, markers of a different category of seller.

What Lilly alleges

These are civil complaints containing unproven allegations. None of the defendants has been found liable, and the claims described here are Lilly's, not findings of fact.

• Lilly alleges that some sellers marketed product as "research use only" while intending it for human use.
• The complaints allege that product is frequently sourced from unregulated foreign manufacturers.

The scale Lilly describes

Alongside the filings, Lilly said it has:

• reported more than 200 entities to the FDA, the DOJ, state attorneys general, law enforcement and professional licensing boards; and
• identified more than 14,000 websites, advertisements, social posts and product listings offering retatrutide across more than 100 countries.

Those are the company's own figures, describing the size of the market it is acting against.

The legal position, stated plainly

Retatrutide remains investigational and is not approved for human use by any regulator. Lilly has indicated it plans to submit a Biologics License Application to the FDA in Q1 2027 - the biologics pathway, not a New Drug Application. Until an approval is granted, no retatrutide-containing product may legally be sold for human use in the United States. That statement holds regardless of how a product is labelled, what a seller claims, or what business type is behind it.

What this section is not

It is not a guide to sellers. This article does not assess, rank, distinguish or vouch for any seller of retatrutide, and nothing here should be read as suggesting that any source is safer, more legitimate or more acceptable than another. There is no legal consumer route to an investigational drug, and we are not describing one. The six named defendants are named because they are named in public court filings - not to steer anyone toward or away from a purchase.

The practical takeaway is narrow and unglamorous: the access environment for retatrutide in August 2026 is narrower and more legally contested than the early-August headlines implied, not wider.

Sources for this section: CNBC, 12 August 2026, Lilly lawsuits obesity drug retatrutide; BioPharma Dive, Lilly lawsuit retatrutide black market obesity drug; Endpoints News, Eli Lilly files first lawsuits over retatrutide black market; FiercePharma.

Where retatrutide actually stands

Retatrutide is a triple agonist, acting on the GIP, GLP-1, and glucagon receptors - a mechanism that has drawn attention in obesity research. It remains investigational and not FDA-approved. The core Phase 3 trials have reported - TRIUMPH-1 and TRIUMPH-4, and TRIUMPH-2 and TRIUMPH-3 together on 23 July 2026 - while TRIUMPH-5, the head-to-head against tirzepatide, and TRIUMPH-6 have not. Both TRIUMPH-2 and TRIUMPH-3 met their primary endpoints against placebo, and Lilly says it is completing the manufacturing and quality package it needs before filing. It has indicated it plans to submit a Biologics License Application to the FDA in Q1 2027; as of 26 October 2026 that submission has not been made. Filing is the beginning of a formal regulatory review, not the end of one; on a realistic reading, an approval would sit in late 2027 to 2028 at the earliest. That matters for how this page should be read: the expanded-access pathway is not a bridge to an imminent launch. It sits in front of a filing that has not happened yet, and a decision that is further out still. No regulator has concluded that retatrutide is safe and effective for general use.

For readers who want the underlying science rather than the news cycle, our retatrutide evidence overview and primer on retatrutide walk through where the data currently stand. The absence of an approved label is also the reason why no approved retatrutide dose exists, and among the people who have received it through trials, why people stop taking retatrutide breaks discontinuation into the five distinct problems it actually is. And for context on how the broader regulatory environment is shifting, see our coverage of the 2026 FDA peptide vote results. For how retatrutide's trial numbers compare with the approved options - and why those comparisons are not head-to-head - see tirzepatide vs retatrutide.

Any decision about weight-management care belongs in a clinical conversation - and for retatrutide specifically, that conversation is about an investigational compound with no lawful route to it, not about a product to be obtained.

Frequently asked questions

Can I get retatrutide right now? For almost everyone, no. A narrow expanded-access pathway exists, but it is limited to a small group of critically ill patients who meet every reported criterion, are backed by a treating physician, and clear Lilly, the FDA, and an IRB. There is no legal way to simply buy retatrutide as a consumer, and any seller claiming otherwise is not operating within this program.

Is it legal to buy retatrutide in the US? No. Retatrutide is investigational: its main Phase 3 weight trials have reported, but it has not been filed for approval, let alone approved. Until an approval is granted, no retatrutide-containing product may legally be sold for human use in the United States. In August 2026 Lilly filed six lawsuits against US sellers and said it had referred more than 200 entities to regulators, prosecutors and licensing boards. Those suits contain unproven allegations, but the underlying legal position - no approval, therefore no lawful human-use sale - is not in dispute.

Does a "research use only" label make it legal? No. Lilly's complaints specifically allege that some sellers used "research use only" labelling while intending the product for human use. A label does not change a drug's regulatory status.

Is expanded access the same as approval? No. Expanded access - also called compassionate use, and here organized as a treatment IND - lets specific patients receive an investigational medicine outside a trial. It does not change the drug's status. Retatrutide remains investigational and not FDA-approved.

Does this mean retatrutide is safe, effective, and available? No. A compassionate-use pathway reflects unmet need in severe cases, not a regulatory conclusion that a drug is safe and effective for general use. It is also not a signal of availability - there is no commercial product to obtain.

When could retatrutide actually be approved? Lilly has signalled plans to submit a Biologics License Application to the FDA in Q1 2027 (not yet submitted as of 26 October 2026) - the biologics pathway rather than a New Drug Application, and later than the end-2026 filing some earlier coverage assumed. A submission opens a review process; it is not an approval and it does not come with a guaranteed date. Realistically that places any approval in late 2027 to 2028 at the earliest. Until one is granted, the drug stays investigational.

Related reading

• Retatrutide: the evidence so far
• Retatrutide explained
• Tirzepatide vs retatrutide
• Are peptides legal now in 2026?
• Is compounded GLP-1 legal?
• Is there a retatrutide dosing guide?
• Why people stop taking retatrutide
• Filed, approved, available - why a medicine's date is really three different dates

Part of The Complete Guide to GLP-1s

Where to start instead. If weight management is on your mind, the useful first step is the same whatever ends up being approved: we recommend starting with baseline bloodwork, then talking the options that are approved today through with your own doctor.

---

This article is educational content, not medical advice. Retatrutide is investigational and not FDA-approved. Expanded access, compassionate use, and a treatment IND are not the same as FDA approval, a prescription, or commercial availability. Until any approval, no retatrutide-containing product may legally be sold for human use in the United States. Litigation described here consists of unproven civil allegations; no defendant has been found liable. No doses or protocols appear here, and nothing here identifies or endorses any source of an investigational compound. Any treatment decision should be made with a qualified clinician. Claims for the Malaysian market are subject to MAB requirements.

References

• STAT News - coverage of Eli Lilly's expanded-access decision for retatrutide (3 August 2026)
• The American Journal of Managed Care (AJMC) - reporting on the retatrutide expanded-access pathway and eligibility criteria
• Becker's Hospital Review - coverage of Lilly's early-access program for retatrutide
• Quartz - reporting on the retatrutide compassionate-use announcement
• TechTimes - coverage emphasizing that the program uses "criteria most patients cannot meet"
• ClinicalTrials.gov - NCT07629401, "Provide Pre-approval Expanded Access of LY3437943"
• CNBC, 12 August 2026 - Lilly files lawsuits over gray-market retatrutide: https://www.cnbc.com/2026/08/12/lilly-lawsuits-obesity-drug-retatrutide.html
• BioPharma Dive - Lilly lawsuit, retatrutide black market: https://www.biopharmadive.com/news/lilly-lawsuit-retatrutide-black-market-obesity-drug/827659/
• Endpoints News - Eli Lilly files first lawsuits over retatrutide black market: https://endpoints.news/eli-lilly-files-first-lawsuits-over-retatrutide-black-market/
• FiercePharma - coverage of the 12 August 2026 retatrutide enforcement filings
• Eli Lilly investor release, 23 July 2026 - "Lilly's triple agonist retatrutide successful in two additional Phase 3 obesity trials": TRIUMPH-2 and TRIUMPH-3 met their primary endpoints versus placebo; CMC package in completion; US BLA submission planned for Q1 2027 (investor.lilly.com)